News

Friedman outlines how dermatologists can track cumulative corticosteroid exposure, identify at-risk patients, and improve patient adherence with handouts.

Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.

Interim ProACt data show adjunctive cariprazine may work within 2 weeks, easing reluctance to augment antidepressant therapy in MDD, Andrew Cutler, MD, says.

This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.

Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.

Jennifer Soung, MD, and Mona Shahriari, MD, discuss diagnosing psoriasis in diverse skin tones and why severity scores overlook dyspigmentation.

Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.

George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.

In this segment from the latest episode of Diabetes Dialogue, Diana Isaacs, PharmD, and Natalie Bellini, DNP, discuss the FDA's recent approval of finerenone for CKD with T1D.

David Berg, MD, discusses his meta-analysis of 3 major trials of dapagliflozin, which determined its efficacy in reducing cardiovascular death risk.

Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.

SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.

EMBARQ-CSU1 and EMBARQ-CSU2 showed sustained reductions in urticaria, with the antibody meeting all primary and key secondary endpoints at Week 12.

The FDA-approved update adds phase 3 HYPERION data on adults diagnosed with PAH within the past year.

Josh Woolley, MD, PhD, explains why current active placebos fail to mask high-dose psilocybin trials and outlines a framework proposed to fix it.

Raj Chovatiya, MD, PhD, on zasocitinib results in the scalp, nails, palms and soles, speed of response and once-daily oral dosing in psoriasis.

Philadelphia-area PAH specialists discuss real-world patient mismatch with trial criteria, drug sequencing, and insurance access barriers.

Kazem Rahimi, MD, discusses his recent IPD analysis highlighting the consistent relative risk reduction of first cardiovascular event with BP-lowering drugs.

van Ingen, of Radboud University Medical Center, discusses the ENCORE trial's patient-reported endpoint for ALIS in MAC lung disease.

Woolley discusses why an active placebo's own therapeutic effects complicate psilocybin trial blinding and outlines next steps for testing UMBRAA.

FDA expands marstacimab approval to children and patients with inhibitors, backed by new BASIS trial data.

Frances Lee, MD, on stigma's role in ALD care and why women may progress to advanced disease faster than men.

van Ingen, of Radboud University Medical Center discusses data showing add-on ALIS improved durable culture conversion in newly diagnosed MAC lung disease.

In this Q&A, Raj Chovatiya, MD, PhD, discusses where zasocitinib fits in the psoriasis treatment algorithm and what high clearance rates mean for patients.

The sNDA for amikacin liposome inhalation suspension is supported by phase 3b ENCORE trial data, with a PDUFA date of January 28, 2027.

Aquestive has resubmitted its needle-free epinephrine film after an FDA rejection over usability, not efficacy. This FAQ covers what changed.

Stay updated with the latest healthcare breakthroughs, including Bayer's finerenone expanding to type 1 diabetes-associated CKD.

Woolley separates intoxication from delirium and defends aggressive masking instead of a shift to comparative efficacy trial designs.